GALC and chronic inflammatory demyelinating polyradiculoneuropathy: Rostami et al. evaluated human serum and CSF for anti-GalC antibodies using four different assays but found no significant differences between patients with MS, Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), healthy controls, or individuals with other neurological diseases, arguing against a disease-specific role for GalC [57].